English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Fingolimod induces neuroprotective factors in human astrocytes

MPS-Authors
/persons/resource/persons80321

Faber,  Hans
Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80580

Weber,  Peter
Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80482

Pütz,  Benno
Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80578

Weber,  Frank
Max Planck Institute of Psychiatry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

art_10.1186_s12974-015-0393-6.pdf
(Any fulltext), 1006KB

Supplementary Material (public)
There is no public supplementary material available
Citation

Hoffmann, F. S., Hofereiter, J., Ruebsamen, H., Melms, J., Schwarz, S., Faber, H., et al. (2015). Fingolimod induces neuroprotective factors in human astrocytes. JOURNAL OF NEUROINFLAMMATION, 12: 184. doi:10.1186/s12974-015-0393-6.


Cite as: https://hdl.handle.net/11858/00-001M-0000-0029-BAC6-6
Abstract
Background: Fingolimod (FTY720) is the first sphingosine-1-phosphate (S1P) receptor modulator approved for the treatment of multiple sclerosis. The phosphorylated active metabolite FTY720-phosphate (FTY-P) interferes with lymphocyte trafficking. In addition, it accumulates in the CNS and reduces brain atrophy in multiple sclerosis (MS), and neuroprotective effects are hypothesized. Methods: Human primary astrocytes as well as human astrocytoma cells were stimulated with FTY-P or S1P. We analyzed gene expression by a genome-wide microarray and validated induced candidate genes by quantitative PCR (qPCR) and ELISA. To identify the S1P-receptor subtypes involved, we applied a membrane-impermeable S1P analog (dihydro-S1P), receptor subtype specific agonists and antagonists, as well as RNAi silencing. Results: FTY-P induced leukemia inhibitory factor (LIF), interleukin 11 (IL11), and heparin-binding EGF-like growth factor (HBEGF) mRNA, as well as secretion of LIF and IL11 protein. In order to mimic an inflammatory milieu as observed in active MS lesions, we combined FTY-P application with tumor necrosis factor (TNF). In the presence of this key inflammatory cytokine, FTY-P synergistically induced LIF, HBEGF, and IL11 mRNA, as well as secretion of LIF and IL11 protein. TNF itself induced inflammatory, B-cell promoting, and antiviral factors (CXCL10, BAFF, MX1, and OAS2). Their induction was blocked by FTY-P. After continuous exposure of cells to FTY-P or S1P for up to 7 days, the extent of induction of neurotrophic factors and the suppression of TNF-induced inflammatory genes declined but was still detectable. The induction of neurotrophic factors was mediated via surface S1P receptors 1 (S1PR1) and 3 (S1PR3). Conclusions: We identified effects of FTY-P on astrocytes, namely induction of neurotrophic mediators (LIF, HBEGF, and IL11) and inhibition of TNF-induced inflammatory genes (CXCL10, BAFF, MX1, and OAS2). This supports the view that a part of the effects of fingolimod may be mediated via astrocytes.